EARNING RECAP

Caterpillar Inc

#CAT 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q2 adjusted $2.83 est. $3.12 $14.43B est. $14.44B -4.48% ($131.91 closing price0 $134.31 $128.45 backs FY19 EPS view of $11.75- $12.75 est. $12.24; Q2 dealer machine/engine inventories machine rose $500M vs. $100M last year
Q1 w/ tax benefit $3.25 est. $2.86 $13.47B est. $13.46B -3.03% ($137.73 closing price) $140.30 $136.56 says Q1 sales increase primarily due to higher sales volume; raises FY19 EPS view to $12.06-$13.06 est. $12.30
#CAT 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted $2.55 est. $2.99 $14.3B est. $14.33B -9.13% ($124.37 closing price) $127.80 $123.15 sees FY19 EPS $11.75- $12.75 est. $12.64;order back log in the end of Q4 $16.5B
Q3 adjusted $2.86 est. $2.85 $13.5B est. $13.29B -7.56% ($118.98 closing) $122.50 $115.62 52 weeks lows; Best quarterly earnings in history; Backs FY18 EPS earnings $11- $12 est. $11.66
Q2 adjusted $2.97 est. $2.73 $14B est. $13.88B -1.97% ($139.75 closing) $146.70 $139.06 raises FY18 adjusted EPS view to $11.00-$12.00 from $10.25-$11.25 FY18 consensus $10.87; announces new $10B repurchase program
Q1 adjusted $2.82 est. $2.08 $12.9B est. $11.98B -6.20% (144.44 closing) $161.10 $143.36 raises FY18 EPS view to $10.25 to $11.25 est. $9.17
#CAT 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted EPS $2.16 vs $1.79 $12.9B vs $11.98B +0.61% to $169.37 $173.10 $162.46 Sees FY18 adjusted EPS $8.25-$9.25 vs $8.19 est
Q3 adjusted EPS $1.95 vs $1.27 $11.4B vs $10.6B +4.98% closed at $138.24 $140.44 $136.63 Raises FY17 adjusted EPS view to about $6.25 form $5.00.
Q2 $1.49 vs $1.26 $11.33B vs $10.93B +5.88% or 6.36 points, Closed at $114.54 114.89 111.80 +5.23% to 113.53 pre market. Raises guidance FY17 EPS view to %5.00 from $3.75
Q1 $1.28 vS 62c est. $9.82B vs $9.26B est +7.86%. Closed at $104.42 $104.89 102.00 Raises guidance. raises FY17 EPS ex-costs to $3.75 from $2.90, consensus $3.25. Stock has running high

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.